MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$150,321K
Net Income
$25,490K
Net Profit Margin
16.96%
EPS
$0.31
Unit: Thousand (K) dollars
Revenue Breakdown
    • Testing
    • Product
    • Biopharmaceutical And Other Biop...
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
150,321
139,071
140,636
131,872
Cost of revenue-Testing
36,309
33,306
33,712*
33,777
Cost of revenue-Product
2,515
1,891
1,661*
3,015
Cost of revenue-Biopharmaceutical And Other
207
8
584*
1,091
Intangible asset amortization - cost of revenue
2,741
2,707
2,707
2,707
Total cost of revenue
41,772
37,912
38,663
40,590
Gross profit
108,549
101,159
101,973
91,282
Research and development
29,442
27,098
20,849
15,981
Selling and marketing
28,263
27,156
25,940
24,455
General and administrative
27,443
23,680
17,367
27,278
Impairment gain
0
-
-0*
0
Intangible asset amortization - operating expenses
421
579
623*
622
Total operating expenses
85,569
78,513
64,778
68,336
Income (loss) from operations
22,980
22,646
37,195
22,946
Other income, net
3,543
7,328
3,439
-4,057
Income before income taxes
26,523
29,974
40,634
18,889
Income tax provision
1,033
1,267
-515
-248
Net income (loss)
25,490
28,707
41,149
19,137
Basic EPS
0.32
0.36
0.52
0.24
Diluted EPS
0.31
0.35
0.489
0.24
Basic Average Shares
79,972,389
79,536,601
79,192,269
78,725,139
Diluted Average Shares
82,059,442
81,313,588
84,153,331
79,691,703
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Biopharmaceutical And OtherBiopharmaceutical Revenue$802K Testing$145,661K (19.14%↑ Y/Y)Product$3,858K (7.23%↑ Y/Y)Biopharmaceutical And Other$802K (-81.36%↓ Y/Y)Total revenue$150,321K (15.49%↑ Y/Y)Gross profit$108,549K (20.92%↑ Y/Y)Total cost of revenue$41,772K (3.41%↑ Y/Y)Income (loss) fromoperations$22,980K (536.22%↑ Y/Y)Other income, net$3,543K (-45.64%↓ Y/Y)Total operatingexpenses$85,569K (-9.96%↓ Y/Y)Cost ofrevenue-Testing$36,309K (12.04%↑ Y/Y)Intangible assetamortization - cost of revenue$2,741K (2.77%↑ Y/Y)Cost ofrevenue-Product$2,515K (43.80%↑ Y/Y)Cost ofrevenue-Biopharmaceutical And Other$207K (-94.20%↓ Y/Y)Income before incometaxes$26,523K (2021.84%↑ Y/Y)Research and development$29,442K (81.03%↑ Y/Y)Selling and marketing$28,263K (11.64%↑ Y/Y)General andadministrative$27,443K (-15.12%↓ Y/Y)Intangible assetamortization - operating...$421K (-32.21%↓ Y/Y)Net income (loss)$25,490K (2701.02%↑ Y/Y)Income tax provision$1,033K (-53.68%↓ Y/Y)

VERACYTE, INC. (VCYT)

VERACYTE, INC. (VCYT)